Biotech firm Odyssey valued at $899.9 million as shares rises in Nasdaq debut
08/05/2026 16:54
May 8 (Reuters) - Odyssey Therapeutics ODTX.O shares rose 11.1% in its Nasdaq debut on Friday, giving the biopharmaceutical firm a valuation of $899.9 million. (Reporting by Prakhar Srivastava in Bengaluru; Editing by Vijay Kishore) ((Prakhar.srivastava2@thomsonreuters.com;))
Recent news on Kailera Therapeutics
See all newsKardigan surges in Nasdaq debut after upsized $400 million IPO (updated)
Brief: Kailera Therapeutics Says Phase 2 Ribupatide Oral Shows Up To 12.1% Mean Weight Loss At 26 Weeks
Advisory: Research alert on Kailera Therapeutics withdrawn
Biotech firm Odyssey valued at $899.9 million as shares rises in Nasdaq debut (updated)
Biotech firm Odyssey valued at $899.9 million as shares rises in Nasdaq debut